These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35352833)

  • 1. Routine noninvasive prenatal screening for fetal Rh D in maternal plasma-A 2-year experience from a single center in Belgium.
    Blomme S; Nollet F; Rosseel W; Bogaard N; Devos H; Emmerechts J; Cauwelier B
    Transfusion; 2022 May; 62(5):1103-1109. PubMed ID: 35352833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of fetal RHD type in plasma of RhD negative pregnant women.
    Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
    Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antenatal
    Clausen FB
    Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.
    Manfroi S; Calisesi C; Fagiani P; Gabriele A; Lodi G; Nucci S; Pelliconi S; Righini L; Randi V
    Blood Transfus; 2018 Nov; 16(6):514-524. PubMed ID: 29757138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands.
    de Haas M; Thurik FF; van der Ploeg CP; Veldhuisen B; Hirschberg H; Soussan AA; Woortmeijer H; Abbink F; Page-Christiaens GC; Scheffer PG; Ellen van der Schoot C
    BMJ; 2016 Nov; 355():i5789. PubMed ID: 27821701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women.
    Dündar Yenilmez E; Kökbaş U; Kartlaşmış K; Kayrın L; Tuli A
    PLoS One; 2018; 13(6):e0197855. PubMed ID: 29874251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
    Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
    Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma.
    Hromadnikova I; Vechetova L; Vesela K; Benesova B; Doucha J; Kulovany E; Vlk R
    Fetal Diagn Ther; 2005; 20(4):275-80. PubMed ID: 15980640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cases of RhD variants RhD*DAU2/DAU6 and RhD*weak D type 4.1 in pregnant women in Saudi Arabia.
    Owaidah A; Aljuhani K; Albasri J; Alsulmi E; Alsaihati T; Alzahrani F
    Acta Biomed; 2023 Mar; 94(S1):e2023080. PubMed ID: 36883669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
    Kent J; Farrell AM; Soothill P
    BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis.
    Clausen FB; Rieneck K; Krog GR; Bundgaard BS; Dziegiel MH
    Methods Mol Biol; 2019; 1885():347-359. PubMed ID: 30506209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prenatal screening service for fetal RHD genotyping to guide prophylaxis: the two-year experience of the Friuli Venezia Giulia region in Italy.
    Londero D; Merluzzi S; Dreossi C; Barillari G
    Blood Transfus; 2023 Mar; 21(2):93-99. PubMed ID: 35848630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal RHD gene determination and dosage analysis by PCR: clinical evaluation.
    Chan FY; Cowley NM; Wolter L; Stone M; Carmody F; Saul A; Hyland CA
    Prenat Diagn; 2001 Apr; 21(4):321-6. PubMed ID: 11288127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive fetal RhD genotyping.
    Clausen FB; Damkjær MB; Dziegiel MH
    Transfus Apher Sci; 2014 Apr; 50(2):154-62. PubMed ID: 24642067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of RhD status and clinical application of non-invasive prenatal determination of fetal RHD in maternal plasma: a 5 year experience in Cyprus.
    Papasavva T; Martin P; Legler TJ; Liasides M; Anastasiou G; Christofides A; Christodoulou T; Demetriou S; Kerimis P; Kontos C; Leontiades G; Papapetrou D; Patroclos T; Phylaktou M; Zottis N; Karitzie E; Pavlou E; Kountouris P; Veldhuisen B; van der Schoot E; Kleanthous M
    BMC Res Notes; 2016 Apr; 9():198. PubMed ID: 27036548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic disease of the fetus and newborn in the molecular era.
    Fasano RM
    Semin Fetal Neonatal Med; 2016 Feb; 21(1):28-34. PubMed ID: 26589360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy.
    Vivanti A; Benachi A; Huchet FX; Ville Y; Cohen H; Costa JM
    Am J Obstet Gynecol; 2016 Nov; 215(5):606.e1-606.e5. PubMed ID: 27393271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
    Müller SP; Bartels I; Stein W; Emons G; Gutensohn K; Köhler M; Legler TJ
    Transfusion; 2008 Nov; 48(11):2292-301. PubMed ID: 18694461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.